Risankizumab: A pilot study of short‐term effectiveness and safety in real clinical practice
Author:
Affiliation:
1. Department of Dermatology Hospital Universitario San Cecilio Granada Spain
2. Department of Dermatology Hospital Universitario Reina Sofía Córdoba Spain
3. Department of Dermatology Hospital Universitario Puerto Real Cádiz Spain
Publisher
Wiley
Subject
Dermatology,General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.14711
Reference8 articles.
1. Update on risankizumab for the treatment of moderate to severe psoriasis
2. Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies
3. A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16‐week real‐life experience during the COVID‐19 pandemic
4. Risankizumab as a promising therapeutic approach in obese patients
5. Successful therapy of psoriasis with risankizumab after previous failure of guselkumab and tildrakizumab;Kromer C;Dermatol Ther,2020
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing;Clinical, Cosmetic and Investigational Dermatology;2023-01
2. Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines;Life;2022-11-14
3. Risankizumab effectiveness and safety in psoriasis patients who failed other biologics: Real-life case series;Indian Journal of Dermatology, Venereology and Leprology;2021-12-24
4. Risankizumab in psoriasis: prior biologics failure does not impact on short-term effectiveness;Expert Opinion on Biological Therapy;2021-12-12
5. Tildrakizumab: short‐term efficacy and safety in real clinical practice;International Journal of Dermatology;2021-10-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3